Three key questions dominate the agency’s Breakthrough Therapy Designation program since its 2012 launch.
Christopher-Paul Milne
Advertisement
Articles by Christopher-Paul Milne
The US drug regulatory system fails to address the country’s most urgent medical needs with the resources appropriate for the task. But change is possible.
Advertisement
Latest Updated Articles
Meeting Unmet Medical Needs: The Disparity DilemmaPublished: February 1st 2015 | Updated:
FDA’s Breakthrough Therapy DesignationPublished: September 8th 2015 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
3
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
4
Pharmaceutical Executive Daily: TrumpRx's Implication on DTC Commercialization
5
